1	Mass Spectrometry-Based Proteomic Profiling of Sonicate Fluid Differentiates
2	Staphylococcus aureus Periprosthetic Joint Infection from Non-Infectious Failure:
3	A pilot study
4	Cody R. Fisher ^{a,b} , Kiran K. Mangalaparthi ^c , Kerryl E. Greenwood-Quaintance ^b ,
5	Matthew P. Abdel ^e , Akhilesh Pandey ^{c,d} , Robin Patel ^{b,f#}
6	^a Mayo Clinic Graduate School of Biomedical Sciences, Department of Immunology, Mayo
7	Clinic, Rochester, Minnesota
8	^b Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo
9	Clinic, Rochester, Minnesota
10	^c Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and
11	Pathology, Mayo Clinic, Rochester, Minnesota
12	^d Manipal Academy of Higher Education, Manipal 576104, Karnataka, India
13	^e Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota
14	^f Division of Public Health, Infectious Diseases and Occupational Medicine, Department of
15	Medicine, Mayo Clinic, Rochester, Minnesota
16	#CORRESPONDING AUTHOR:
17	Robin Patel, M.D.
18	Division of Clinical Microbiology, Mayo Clinic,
19	200 First Street SW, Rochester, MN 55905
20	507-538-0579
21	email: patel.robin@mayo.edu
22	KEYWORDS: Label-free quantitation, periprosthetic joint infection, quantitative proteomics,
23	sonicate fluid, total joint arthroplasty

24 **TOTAL WORD COUNT: 5816**

25 ABSTRACT

Purpose: This study aims to use proteomic profiling of sonicate fluid samples to compare host response during *Staphylococcus aureus*-associated periprosthetic joint infection (PJI) and noninfected arthroplasty failure (NIAF) and investigate novel biomarkers to increase diagnostic accuracy.

Experimental Design: In this pilot study, eight sonicate fluid samples (four from NIAF and four from *Staphylococcus aureus* PJI) were studied. Samples were reduced, alkylated and trypsinized overnight, followed by analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS) on a high-resolution Orbitrap Eclipse mass spectrometer. MaxQuant software suite was used for protein identification, filtering, and label-free quantitation.

Results: Principal component analysis of the identified proteins clearly separated *S. aureus* PJI and NIAF samples. Overall, 810 proteins were quantified in any three samples from each group and 35 statistically significant differentially abundant proteins (DAPs) were found (2-sample ttest p-values ≤ 0.05 and \log_2 fold-change values ≥ 2 or ≤ -2). Gene ontology pathway analysis found that microbial defense responses, specifically those related to neutrophil activation, were increased in *S. aureus* PJI compared to NIAF samples.

Conclusion and Clinical Relevance: Proteomic profiling of sonicate fluid using LC-MS/MS,
 alone or in combination with complementary protein analyses, differentiated *S. aureus* PJI and
 NIAF in this pilot study.

44 ABBREVIATIONS

- 45 **PJI:** periprosthetic joint infection
- 46 **NIAF:** non-infectious arthroplasty failure
- 47 **DAPs:** differentially abundant proteins
- 48 LC-MS/MS: liquid chromatography-tandem mass spectrometry
- 49 CCL20: chemokine ligand 20
- 50 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
- 51 LTF: lactotransferrin
- 52 LCN2: lipocalin-2
- 53 MPO: myeloperoxidase
- 54 **S100A9:** calprotectin-A9
- 55 **S100A8:** calprotectin-A8
- 56 **CTSG:** cathepsin G
- 57 ELANE: neutrophil elastase
- 58 **RNASE3:** eosinophil cationic protein
- 59 ERN1: endoplasmic reticulum to nucleus signaling 1
- 60 MMP9: matrix metalloproteinase-9
- 61 LYZ: lysozyme C
- 62 HP: haptoglobin
- 63 LMNB1: lamin-B1
- 64 **PYGL:** glycogen phosphorylase, liver form
- 65 LRG1 leucine-rich alpha-2-glycoprotein
- 66 CRTAC1: cartilage acidic protein 1
- 67 MCAM: cell surface glycoprotein MUC18

- 68 IFI30: IFI30 lysosomal thiol reductase
- 69 SPP1: osteopontin
- 70 HEXB: beta-hexosaminidase subunit beta
- 71 **PRG4** proteoglycan 4
- 72 **RNASE1:** ribonuclease pancreatic
- 73 **DCD:** dermcidin
- 74 **CD44:** CD44 antigen
- 75 ANXA2: annexin A2
- 76 SERPINB6: serpin B6
- 77 BCAT1: branched-chain-amino-acid aminotransferase
- 78 DLST: dihydrolipoamide S-succinyltransferase
- 79 HSPB1: heat shock protein beta-1
- 80 **EEA1:** early endosome antigen 1
- 81 COL1A2: collagen alpha-2(l) chain
- 82 **FABP5:** fatty acid-binding protein, epidermal
- 83 **FBP1:** fructose-1,6-bisphosphatase 1
- 84 **FABP3:** fatty acid-binding protein, heart
- 85 **CTSD:** cathepsin D
- 86 **PEA:** proximity extension assay
- 87 **TCEP:** tris(2-carboxyethyl)phosphine
- 88 **FDR:** false discovery rate

89 STATEMENT OF CLINICAL SIGNIFICANCE

- 90 Periprosthetic joint infection (PJI) is a major complication of joint arthroplasty. There is no
- 91 perfect assay for differentiating PJI from non-infectious arthroplasty failure (NIAF). Although
- some studies have recently employed 'omics technologies, further work is needed to discover
- novel and sensitive biomarkers and increase accuracy. A comprehensive proteomic analysis of
- sonicate fluid from PJI, a specimen derived from sonication of resected implants to sample
- 95 their surfaces, is not yet reported.

96 1. INTRODUCTION

Periprosthetic joint infection (PJI) is a major cause of arthroplasty failure after total knee or hip 97 replacement surgery. Of the estimated 7 million Americans living with a total knee or hip 98 arthroplasty as of 2010, about 1-2% will go on to get a PJI [1-5]. As the number of individuals who 99 undergo arthroplasty surgery continues to rise, so will the number of PJIs, resulting in extended 100 101 hospital stays, increased antimicrobial usage, and an estimated \$1.85 billion in annual healthcare costs by 2030 [6-9]. Staphylococcus aureus is a common cause of PJI, associated 102 with robust biofilm production, production of numerous virulence factors, and resistance to 103 antimicrobial agents and the host immune response ^[1,2,10-15]. 104

105 Some PJI cases can be difficult to differentiate from non-infectious arthroplasty failure (NIAF) ^[16-21]. Typically, arthroplasty failure is treated with resection of the failed implant and one-106 or two-stage revision surgery or debridement and implant retention, alongside an extended 107 108 course of antimicrobial agents ^[1,22-24]. Microbial- and host-based assays are used to diagnose PJI. Microbial diagnostics may be limited by negative growth in culture or negative results of 109 molecular diagnostics, or conversely, falsely-positive results as a result of detection of 110 contaminants^[25]. Additional host-derived biomarkers for PJI, such as erythrocyte sedimentation 111 rate in blood; nucleated cell count and neutrophil percentage in synovial fluid; and intraoperative 112 tissue histology and purulence, can provide evidence of underlying infection ^[1,22,26]. Host 113 proteomic profiling has also been shown to have the potential to differentiate PJI from NIAF, with 114 increased expression of c-reactive protein, D-dimer, chemokine ligand 20 (CCL20), calprotectin, 115 lipocalin, lactotransferrin, and many others, in PJI compared to NIAF patient samples ^[26-35]. 116 Measurement of one protein, alpha-defensin, in synovial fluid has been approved by the United 117 States Food and Drug Administration as an aid for the detection of PJI ^[33,36]. 118

medRxiv preprint doi: https://doi.org/10.1101/2022.12.28.22284010; this version posted December 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Multi-omics approaches have recently been investigated as potential alternatives to 119 overcome limitations of currently used diagnostic tools [26,29,37-40]. Previous studies have shown 120 that liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based profiling may be able 121 to differentiate synovial fluid samples from PJI and NIAF patients ^[31,41]. Analysis of sonicate fluid, 122 a sample-type that directly interrogates the site of infection - the implant surface -, may 123 124 hypothetically allow for enhanced differentiation of infected and non-infected individuals and potentially PJI biomarker discovery ^[37,40,42-44]. Mass spectrometry-based proteomic analysis 125 provides an unbiased and in-depth overview of the protein expression alterations in biological 126 127 samples. Our group has previously employed mass spectrometry-based proteomics in developing assays of potential diagnostic utility ^[45,46] and in studying host response to severe 128 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection ^[47,48]. This pilot study 129 was aimed to evaluate the feasibility of proteomic analysis of sonicate fluid to reflect the host 130 response to PJI. The advancement of proteomics-based profiling of patient samples during PJI 131 132 could yield novel insights into underlying biological interactions.

133 2. MATERIAL AND METHODS

134 **2.1 Sonicate fluid harvest and cohort**

Sonicate fluid samples were collected between October 2013 and July 2017 from patients undergoing revision total hip or knee arthroplasty; arthroplasty components were removed and subjected to sonication for clinical purposes, as previously described; their use in this study was approved by the Mayo Clinic Institutional Review Board (09-000808) (23). Four NIAF and four *S. aureus* PJI sonicate fluid samples were analyzed. Infection status was determined by the 2018 Musculoskeletal Infection Society and International Consensus Meeting criteria ^[49].

141 2.2 Protein extraction and LC-MS/MS analysis

142 100 µl of sonicate fluid samples were adjusted to 0.2% Rapigest followed by heating at 90 °C for 5 minutes. Samples were then reduced with 5 mM tris(2-carboxyethyl)phosphine (TCEP) for 143 45 minutes at room temperature and alkylated with 20 mM lodoacetamide for 25 minutes in the 144 dark. Trypsin enzyme was added in the ratio of 1:20 for overnight digestion at 37 °C. Following 145 C₁₈ cleanup, 2 µg of peptides were subjected to quantitative LC-MS/MS analysis on a high-146 resolution Orbitrap Eclipse Tribrid mass spectrometer connected to UltiMate 3000 RSLC nano 147 system (Thermo Scientific, Waltham, MA). Separation of peptides includes initial trapping on a 148 trap column (PepMap C18, 2 cm × 100 µm, 100 Å, Thermo Scientific, San Jose, CA) using 0.1% 149 formic acid (solvent A) followed by gradient elution (3% to 28% to 40%) using acetonitrile, 0.1% 150 formic acid (solvent B) on an analytical column (EasySpray 50 cm × 75 µm, C18 1.9 µm,100 Å, 151 Thermo Scientific, San Jose, CA). Each run was started with equilibration of both columns for 5 152 minutes and the overall time for each run was 240 minutes. As the peptides were eluting, the 153 Orbitrap was operated in a data dependent mode with a cycle time of 2 seconds. Initially, the 154 precursor MS scan was recorded for 350-1500 m/z using a normalized AGC target of 100%, 155

injection time of 50 ms and 60,000 resolution. Precursors with a minimum intensity threshold of 156 20,000 and charge states 2-7 were taken for MS/MS starting from high intensity precursors. 157 158 Monoisotopic precursor selection was also enabled. Quadrupole was used for precursor isolation with 1.6 m/z isolation width and fragmented with normalized HCD energy of 28% and 159 resulting fragment ions was recorded in Orbitrap analyzer. Fragment ion spectrum was recorded 160 161 at 15,000 resolution using normalized AGC target of 200% and maximum injection time of 120 ms. Dynamic exclusion of 30 seconds was used to prevent repeated fragmentation of the 162 precursor ions. 163

164 2.3 LC-MS/MS raw data analysis

MaxQuant software suite (V 2.0.1.0) was used for protein identification and guantitation. 165 166 Database searching was performed against human UniProt protein database with in silico trypsin digestion set to be specific and maximum of 2 missed cleavages allowed. Default mass tolerance 167 settings of 20 pm for first search and 4.5 ppm for main search were used. Oxidation (Methionine) 168 and protein N-terminal acetylation were used as dynamic modifications, whereas 169 carbamidomethylation (cysteine) was used as static modification. Proteins were filtered at 1% 170 protein-level false discovery rate (FDR). LFQ algorithm within MaxQuant was used for label-free 171 guantitation and match between the runs option was enabled with match time window of 1 minute 172 to reduce missing values. Finally, label-free quantified values were logarithmized and proteins 173 174 not quantified in at least three samples in each group were eliminated.

2.4 Data organization and statistical analysis

Quantitative data were organized and graphed in RStudio v1.2.5042 ^[50] using the R-packages "ComplexHeatmap" ^[51] for heatmap creation and "Factoextra" ^[52] for principal component analysis. Protein-specific analyses were conducted, and a volcano plot created in Graphpad

Prism 9 v9.2.0 (San Diego, CA). Enrichr was used for gene ontology pathway analysis ^[53-55]. Statistical significance was determined using 2-sample t-test with multiple hypothesis correction (p-values ≤ 0.05 and \log_2 fold-change values ≥ 2 or ≤ -2).

182 3. RESULTS AND DISCUSSION

183 **3.1 Cohort differential protein abundance characterization**

In this study, quantitative LC-MS/MS analysis was used to characterize the host proteomic 184 profile of four NIAF and four S. aureus PJI sonicate fluid samples and determine whether NIAF 185 and S. aureus PJI-associated samples can be differentiated. Eight hundred and ten proteins 186 were quantified in at least three of four samples each of S. aureus PJI and NIAF cases, of which 187 188 35 differentially abundant proteins (DAPs) were identified (Table 1, Figure 1). Fifteen DAPs were increased in S. aureus PJI compared to NIAF samples, including lactotransferrin (LTF) [log2fold-189 change = 5.2], lipocalin-2 (LCN2) $[log_2 fold-change = 5.0]$, myeloperoxidase (MPO) $[log_2 fold-change = 5.0]$ 190 191 change = 4.9], calprotectin-A9 (S100A9 subunit) [log2fold-change = 4.5], calprotectin-A8 (S100A8 subunit) $[log_2fold-change = 4.0]$, cathepsin G (CTSG) $[log_2fold-change = 4.0]$, 192 neutrophil elastase (ELANE) [log₂fold-change = 3.8], eosinophil cationic protein (RNASE3) 193 $[log_2 fold-change = 3.6]$, endoplasmic reticulum to nucleus signaling 1 (ERN1) $[log_2 fold-change$ 194 = 3.2], matrix metalloproteinase-9 (MMP9) [log₂fold-change = 2.9], lysozyme C (LYZ) [log₂fold-195 change = 2.7], haptoglobin (HP) [log₂fold-change = 2.6], lamin-B1 (LMNB1) [log₂fold-change = 196 2.5], glycogen phosphorylase, liver form (PYGL) [log2fold-change = 2.5], leucine-rich alpha-2-197 glycoprotein (LRG1) [log₂fold-change = 2.2] (Table 1). 198

Twenty of the 35 DAPs were decreased in *S. aureus* PJI compared to NIAF sonicate fluid samples (Table 1, Figure 1), including cartilage acidic protein 1 (CRTAC1) [log₂fold-change = -5.3], cell surface glycoprotein MUC18 (MCAM) [log₂fold-change = -4.2], IFI30 lysosomal thiol 202 reductase (IFI30) [log₂fold-change = -2.8], osteopontin (SPP1) [log₂fold-change = -2.7], betahexosaminidase subunit beta (HEXB) [log2fold-change = -2.6], proteoglycan 4 (PRG4) [log2fold-203 change = -2.6], ribonuclease pancreatic (RNASE1) [log₂fold-change = -2.5], dermcidin (DCD) 204 [log₂fold-change = -2.5], CD44 antigen (CD44) [log₂fold-change = -2.5], annexin A2 (ANXA2) 205 [log2fold-change = -2.4], serpin B6 (SERPINB6) [log2fold-change = -2.4], branched-chain-amino-206 207 acid aminotransferase (BCAT1) [log₂fold-change = -2.3], dihydrolipoamide Ssuccinyltransferase (DLST) $[log_2fold-change = -2.3]$, heat shock protein beta-1 (HSPB1) 208 [log₂fold-change = -2.1], early endosome antigen 1 (EEA1) [log₂fold-change = -2.1], collagen 209 210 alpha-2(I) chain (COL1A2) [log₂fold-change = -2.1], fatty acid-binding protein, epidermal (FABP5) [log2fold-change = -2.1], fructose-1,6-bisphosphatase 1 (FBP1) [log2fold-change = -211 2.0], fatty acid-binding protein, heart (FABP3) [log₂fold-change = -2.0], cathepsin D (CTSD) 212 $[log_2 fold-change = -2.0].$ 213

Unsupervised clustering analysis of the DAPs showed distinct pattern of expression between *S. aureus* PJI and NIAF sonicate fluid samples. (Figure 2A). Differential clustering was also observed via principal component analysis, where *S. aureus* PJI and NIAF sonicate fluid samples were separated along dimension 1, accounting for 81.8% of the total variation of the dataset (Figure 2B).

3.2 Gene ontology analyses of differentially abundant proteins

To better understand the functional outcome of sonicate fluid DAPs in PJI *versus* NIAF, gene ontology analysis was conducted ^[53-55]. Unsurprisingly, biological processes related to neutrophil antimicrobial activity, such as activation and degranulation, were increased in *S. aureus* PJI compared to NIAF sonicate fluid samples. Overall antimicrobial responses against bacteria and fungi were also increased in *S. aureus* PJI (Figure 3A). Next, molecular functions

enriched among DAPs were examined. Inflammatory pathways, such as those related to 225 peptidase activity and RAGE receptor binding were increased in S. aureus PJI samples. Metal 226 ion-binding pathways were also increased in S. aureus PJI samples. In fact, many of the DAPs 227 most increased in S. aureus PJI, such as LTF, LCN2, and S100A8/A9, are known metal ion 228 sequestration proteins reported to be important for the antimicrobial nutritional immunity 229 response in other infection types [56-58]. Though increases of metal ion binding proteins have 230 recently been shown to be clinical biomarkers of PJI biomarkers ^[27,28,30,31,59,60], the functional 231 role of nutritional immunity during PJI is an area needing further investigation. 232

233 **3.3 Further validation of differentially abundant proteins**

234 While the mass-spectrometry-based proteomic profiling described here identified DAPs and differentiated S. aureus and NIAF sonicate fluid samples, the sample size was low, and further 235 validation was necessary. To do so, results were compared to previous transcriptomic and 236 proteomic analyses of sonicate fluid samples conducted by our group. Transcriptomic analysis 237 of eight S. aureus PJI and forty NIAF sonicate fluid samples, including the eight that underwent 238 LC-MS/MS here, has been recently reported ^[40]. Of the thirty-five DAPs found via LC-MS/MS, 239 18 had differentially expressed transcripts via RNA-sequencing. In all but one recapitulated case, 240 whether the target was up- or downregulated in S. aureus PJI compared to NIAF remained 241 242 consistent. MMP9 was found to have increased protein abundance but decreased transcriptomic abundance in *S. aureus* PJI compared to NIAF samples. 243

Proteomic profiling of 200 sonicate fluid samples, including the eight that underwent LC-MS/MS, was recently reported using the proximity extension assay (PEA) platform from Olink Proteomics (Uppsala, Sweden) ^[34,61]. PEA showed that, of the 92 proteins included in the Olink Inflammation Panel, 37 DAPs were found when comparing PJI and NIAF samples ^[34].

Interestingly, there was no overlap across the 37 DAPs identified through PEA platform to the 248 35 DAPs identified by LC-MS/MS analysis. This lack of overlap is explained by specific 249 characteristics of each platform. PEA is a targeted method that uses antibodies conjugated to 250 oligonucleotides and PCR amplification to process and quantify proteins, allowing for 251 assessment of low-concentration proteins. However, this analysis is limited to detection to the 252 specific protein targets included in the panel ^[61]. In contrast, LC-MS/MS is an unbiased approach, 253 which can quantify proteins in a global fashion that are above the detection limit ^[62]. Thus, a 254 255 targeted approach like PEA is complementary to an LC-MS/MS approach. Thus, combining LC-256 MS/MS with PEA provides a holistic proteomic profile for protein biomarker discovery.

257 Lastly, results were compared to those found by Li et al. which analyzed 51 PJI and 66 non-PJI synovial fluid samples identified by LC-MS/MS^[41]. Of the 35 DAPs found in sonicate 258 fluid, 15, including LTF, MPO, S100A9, CTSG, S100A8, ELANE, MMP9, HP, PYGL, CTSD, 259 FABP5, BCAT1, PRG4, HEXB, and CRTAC1, were also found in synovial fluid. Proteomic 260 analysis of synovial fluid revealed 281 DAPs, a higher number than identified herein in sonicate 261 fluid, with the caveat that more patients and bacterial species causing PJI were analyzed in the 262 synovial fluid study. That proteomic analyses of sonicate and synovial fluid were not fully 263 concordant affirms the potential value of interrogating both sample types, though ideally synovial 264 265 and sonicate fluids from the same patients, collected at the same time and analyzed using the same methods, should be analyzed. 266

267 4. CONCLUDING REMARKS

Overall, results from this study indicate that proteomic profiling of sonicate fluid using mass spectrometry-based proteomic analysis differentiates *S. aureus* PJI and NIAF samples. This

- study supports the concept of conducting larger and more thorough future proteomic profiling
- studies using combinational analyses and complementary sample-types.

272 ACKNOWLEDGEMENTS

- 273 This research was supported by the National Institute of Arthritis and Musculoskeletal and Skin
- 274 Diseases of the National Institutes of Health under Award Number NIH R01 AR056647. CF
- was supported by the Mayo Clinic Graduate School of Biomedical Sciences and the Ph.D.
- 276 Training Grant in Basic Immunology (NIAID T32 AI07425-25). The content is solely the
- responsibility of the authors and does not necessarily represent the official views of the NIH.
- 278 We would like to acknowledge Suzannah Schmidt-Malan, M.S., Melissa Karau, M.S., and the
- 279 rest of the Mayo Clinic Infectious Diseases Research Laboratory for accessioning and
- 280 maintaining the sonicate fluid biobank.

281 PATIENT CONSENT STATEMENT

The study was approved by the Mayo Clinic Institutional Review Board (#09-000808).

283 AUTHORS' CONTRIBUTIONS

CF's roles were conceptualization, data curation, formal analysis, investigation, visualization, 284 writing – original draft, and writing – review & editing. KM's roles were mass spectrometry 285 analysis, data analysis and visualization, and writing - review & editing. KG's roles were project 286 administration, supervision, and writing – review & editing. MA's roles were resource provision 287 and writing – review & editing. AP's roles were resource provision, supervision, and writing – 288 review & editing. RP's roles were conceptualization, funding acquisition, project administration, 289 290 resource provision, supervision, and writing - review & editing. All authors read and approved the final manuscript. 291

292 CONFLICT OF INTEREST

RP reports grants from ContraFect, TenNor Therapeutics Limited, and BioFire. RP is a 293 consultant to PhAST, Torus Biosystems, Day Zero Diagnostics, Mammoth Biosciences, and 294 HealthTrackRx; monies are paid to Mayo Clinic. Mayo Clinic and RP have a relationship with 295 Pathogenomix. RP has research supported by Adaptive Phage Therapeutics. Mayo Clinic has 296 297 a royalty-bearing know-how agreement and equity in Adaptive Phage Therapeutics. RP is also a consultant to Netflix, Abbott Laboratories, and CARB-X. In addition, RP has a patent on 298 Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication 299 300 with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. RP receives honoraria from the NBME, Up-to-Date and the Infectious Diseases Board 301 Review Course. MPA receives royalties from Stryker on certain hip and knee products and 302 serve on the AAOS Board of Directors. All other authors report no conflicts of interest. 303

304 DATA AVAILABILITY STATEMENT

The mass spectrometry proteomics data have been deposited to the Proteome Xchange Consortium via the PRIDE partner repository with the dataset identifier PXD038928.

307 **REFERENCES**

- [1] Tande, A. J., & Patel, R. (2014). Prosthetic joint infection. *Clin Microbiol Rev, 27*(2), 302-345.
 doi: 10.1128/CMR.00111-13
- [2] Zimmerli, W. (2006). Infection and musculoskeletal conditions: Prosthetic-joint-associated
 infections. Best Pract Res Clin Rheumatol, 20(6), 1045-1063. doi:
 10.1016/j.berh.2006.08.003
- [3] Trampuz, A., & Widmer, A. F. (2006). Infections associated with orthopedic implants. *Curr Opin Infect Dis*, *19*(4), 349-356. doi: 10.1097/01.qco.0000235161.85925.e8
- [4] Shuman, E. K., A, U., & Malani, P. N. (2012). Management and prevention of prosthetic joint
 infection. *Infect Dis Clin North Am, 26(1):29-39.* doi: 10.1016/j.idc.2011.09.011.
- [5] Maradit Kremers, H., Larson, D. R., Crowson, C. S., Kremers, W. K., Washington, R. E.,
 Steiner, C. A., . . . Berry, D. J. (2015). Prevalence of total hip and knee replacement in
 the United States. *The Journal of bone and joint surgery. American volume*, *97*(17), 13861397. doi: 10.2106/JBJS.N.01141
- [6] Kurtz, S., Ong, K., Lau, E., Mowat, F., & Halpern, M. (2007). Projections of primary and
 revision hip and knee arthroplasty in the United States from 2005 to 2030. *The Journal of bone and joint surgery. American volume, 89*(4), 780-785. doi: 10.2106/JBJS.F.00222
- [7] Gutowski, C. J., Chen, A. F., & Parvizi, J. (2016). The incidence and socioeconomic Impact
 of periprosthetic joint infection: United States perspective *Periprosthetic Joint Infections* (pp. 19-26): Springer.
- [8] Jason Akindolire, M., Morcos, M. W., Howard, J. L., Lanting, B. A., & Vasarhelyi, E. M. (2020).
 The economic impact of periprosthetic infection in total hip arthroplasty. *Can J Surg*, 63(1), E52-E56.
- [9] Premkumar, A., Kolin, D. A., Farley, K. X., Wilson, J. M., McLawhorn, A. S., Cross, M. B., &
 Sculco, P. K. (2021). Projected economic burden of periprosthetic joint infection of the hip
 and knee in the United States. *J Arthroplasty*, *36*(5), 1484-1489 e1483. doi:
 10.1016/j.arth.2020.12.005
- [10] Benito, N., Franco, M., Ribera, A., Soriano, A., Rodriguez-Pardo, D., Sorlí, L., . . . Puente,
 A. (2016). Time trends in the aetiology of prosthetic joint infections: a multicentre cohort
 study. *Clin Microbiol Infect,* 22(8), 732.e731-732.e738. doi:
 <u>https://doi.org/10.1016/j.cmi.2016.05.004</u>
- [11] Hsieh, P.-H., Lee, M. S., Hsu, K.-Y., Chang, Y.-H., Shih, H.-N., & Ueng, S. W. (2009). Gram negative prosthetic joint infections: Risk factors and outcome of treatment. *Clin Infect Dis*,
 49(7), 1036-1043. doi: 10.1086/605593
- [12] Corvec, S., Portillo, M. E., Pasticci, B. M., Borens, O., & Trampuz, A. (2012). Epidemiology
 and new developments in the diagnosis of prosthetic joint infection. *Int J Artif Organs,* 35(10), 923-934. doi: 10.5301/ijao.5000168
- [13] Schilcher, K., & Horswill, A. R. (2020). Staphylococcal biofilm development: Structure,
 regulation, and treatment strategies. *Microbiol Mol Biol Rev, 84*(3), e00026-00019. doi:
 10.1128/MMBR.00026-19
- [14] Arciola, C. R., Campoccia, D., & Montanaro, L. (2018). Implant infections: Adhesion, biofilm
 formation and immune evasion. *Nat Rev Microbiol, 16*(7), 397-409. doi: 10.1038/s41579 018-0019-y
- [15] Stevoska, S., Himmelbauer, F., Stiftinger, J., Stadler, C., Pisecky, L., Gotterbarm, T., &
 Klasan, A. (2022). Significant difference in antimicrobial resistance of bacteria in septic

- revision between total knee arthroplasty and total hip arthroplasty. *Antibiotics, 11*(2), 249. doi: 10.3390/antibiotics11020249
- [16] Bonnin, M., Deschamps, G., Neyret, P., & Chambat, P. (2000). [Revision in non-infected
 total knee arthroplasty: An analysis of 69 consecutive cases]. *Revue de chirurgie orthopedique et reparatrice de l'appareil moteur, 86*(7), 694-706.
- [17] Kelmer, G., Stone, A. H., Turcotte, J., & King, P. J. (2021). Reasons for revision: Primary
 total hip arthroplasty mechanisms of failure. *J Am Acad Orthop Surg, 29*(2), 78-87. doi:
 10.5435/JAAOS-D-19-00860
- [18] Mathis, D. T., Lohrer, L., Amsler, F., & Hirschmann, M. T. (2021). Reasons for failure in
 primary total knee arthroplasty An analysis of prospectively collected registry data. J
 Orthop, 23, 60-66. doi: 10.1016/j.jor.2020.12.008
- [19] Athanasou, N. A. (2016). The pathobiology and pathology of aseptic implant failure. *Bone Joint Res*, *5*(5), 162-168. doi: 10.1302/2046-3758.55.BJR-2016-0086
- [20] Kenney, C., Dick, S., Lea, J., Liu, J., & Ebraheim, N. A. (2019). A systematic review of the
 causes of failure of revision total hip arthroplasty. *J Orthop, 16*(5), 393-395. doi:
 10.1016/j.jor.2019.04.011
- [21] Gazendam, A., Wood, T. J., Tushinski, D., & Bali, K. (2022). Diagnosing periprosthetic joint
 infection: A scoping review. *Curr Rev Musculoskelet Med, 15*(3), 219-229. doi:
 10.1007/s12178-022-09751-w
- [22] Osmon, D. R., Berbari, E. F., Berendt, A. R., Lew, D., Zimmerli, W., Steckelberg, J. M., ...
 America, I. D. S. o. (2013). Diagnosis and management of prosthetic joint infection:
 clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis*, 56(1), e1-e25. doi: 10.1093/cid/cis803
- [23] Kuzyk, P. R., Dhotar, H. S., Sternheim, A., Gross, A. E., Safir, O., & Backstein, D. (2014).
 Two-stage revision arthroplasty for management of chronic periprosthetic hip and knee
 infection: techniques, controversies, and outcomes. *J Am Acad Orthop Surg*, 22(3), 153 164. doi: 10.5435/JAAOS-22-03-153
- [24] Li, C., Renz, N., & Trampuz, A. (2018). Management of periprosthetic joint infection. *Hip Pelvis, 30*(3), 138-146. doi: 10.5371/hp.2018.30.3.138
- [25] Parvizi, J., Ghanem, E., Menashe, S., Barrack, R. L., & Bauer, T. W. (2006). Periprosthetic
 infection: what are the diagnostic challenges? *The Journal of bone and joint surgery. American volume, 88 Suppl 4*(suppl_4), 138-147. doi: 10.2106/JBJS.F.00609
- [26] Keemu, H., Vaura, F., Maksimow, A., Maksimow, M., Jokela, A., Hollmén, M., & Mäkelä, K.
 (2021). Novel biomarkers for diagnosing periprosthetic joint infection from synovial fluid and serum. *JBJS Open Access*, 6(2).
- [27] Hantouly, A. T., Salameh, M., Toubasi, A. A., Salman, L. A., Alzobi, O., Ahmed, A. F., ...
 Ahmed, G. (2022). Synovial fluid calprotectin in diagnosing periprosthetic joint infection:
 A meta-analysis. *Int Ortho, 46*(5), 971-981. doi: 10.1007/s00264-022-05357-6
- [28] Wouthuyzen-Bakker, M., Ploegmakers, J. J. W., Ottink, K., Kampinga, G. A., Wagenmakers Huizenga, L., Jutte, P. C., & Kobold, A. C. M. (2018). Synovial calprotectin: An
 inexpensive biomarker to exclude a chronic prosthetic joint infection. *J Arthroplasty*, 33(4),
 1149-1153. doi: <u>https://doi.org/10.1016/j.arth.2017.11.006</u>
- Sharma, K., Ivy, M., Block, D. R., Abdel, M. P., Hanssen, A. D., Beauchamp, C., ... Patel,
 R. (2020). Comparative analysis of 23 synovial fluid biomarkers for hip and knee
 periprosthetic joint infection detection. J Orthop Res, 38(12), 2664-2674. doi:
 10.1002/jor.24766

- [30] Vergara, A., Fernandez-Pittol, M. J., Munoz-Mahamud, E., Morata, L., Bosch, J., Vila, J., . .
 Casals-Pascual, C. (2019). Evaluation of lipocalin-2 as a biomarker of periprosthetic joint infection. *J Arthroplasty*, *34*(1), 123-125. doi: 10.1016/j.arth.2018.09.047
- [31] Wang, C., Wang, Q., Li, R., Qin, J., Song, L., Zhang, Q., ... Wang, C. (2019). LTF, PRTN3,
 and MNDA in synovial fluid as promising biomarkers for periprosthetic joint infection:
 Identification by quadrupole orbital-trap mass spectrometry. *J Bone Joint Surg*, *101*(24).
- 404 [32] Shahi, A., & Parvizi, J. (2017). The role of biomarkers in the diagnosis of periprosthetic joint 405 infection. *EFORT open reviews*, 1(7), 275-278. doi: 10.1302/2058-5241.1.160019
- [33] Pupaibool, J., Fulnecky, E. J., Swords, R. L., Jr., Sistrunk, W. W., & Haddow, A. D. (2016).
 Alpha-defensin-novel synovial fluid biomarker for the diagnosis of periprosthetic joint infection. *Int Orthop, 40*(12), 2447-2452. doi: 10.1007/s00264-016-3306-0
- [34] Fisher, C. R., Salmons, H. I., Mandrekar, J., Greenwood-Quaintance, K. E., Abdel, M. P., &
 Patel, R. (2022). A 92 protein inflammation panel performed on sonicate fluid
 differentiates periprosthetic joint infection from non-infectious causes of arthroplasty
 failure *in revision*.
- [35] Huang, Z., Zhang, Z., Li, M., Li, W., Fang, X., & Zhang, W. (2022). Synovial fluid neutrophil
 gelatinase-associated lipocalin can be used to accurately diagnose prosthetic joint
 infection. *Int J Infect Dis, 123*, 170-175. doi: 10.1016/j.ijid.2022.08.009
- [36] Deirmengian, C., Madigan, J., Kallur Mallikarjuna, S., Conway, J., Higuera, C., & Patel, R.
 (2021). Validation of the alpha defensin lateral flow test for periprosthetic joint infection.
 The Journal of bone and joint surgery. American volume, 103(2), 115-122. doi: 10.2106/JBJS.20.00749
- [37] Gomez, E., Cazanave, C., Cunningham, S. A., Greenwood-Quaintance, K. E., Steckelberg,
 J. M., Uhl, J. R., . . . Patel, R. (2012). Prosthetic joint infection diagnosis using broad range PCR of biofilms dislodged from knee and hip arthroplasty surfaces using
 sonication. *J Clin Microbiol, 50*(11), 3501-3508. doi: 10.1128/JCM.00834-12
- [38] Thoendel, M. J., Jeraldo, P. R., Greenwood-Quaintance, K. E., Yao, J. Z., Chia, N.,
 Hanssen, A. D., . . . Patel, R. (2018). Identification of prosthetic joint infection pathogens
 using a shotgun metagenomics approach. *Clin Infect Dis, 67*(9), 1333-1338. doi:
 10.1093/cid/ciy303
- [39] Korn, M. F., Stein, R. R., Dolf, A., Shakeri, F., Buness, A., Hilgers, C., . . . Schildberg, F. A. 428 (2020). High-dimensional analysis of immune cell composition predicts periprosthetic joint 429 430 infections and dissects its pathophysiology. Biomedicines, 8(9), 358. doi: 10.3390/biomedicines8090358 431
- [40] Masters, T. L., Bhagwate, A. V., Dehankar, M. K., Greenwood-Quaintance, K. E., Abdel, M.
 P., Mandrekar, J. N., & Patel, R. (2022). Human transcriptomic response to periprosthetic
 joint infection. *Gene, 825*, 146400. doi: 10.1016/j.gene.2022.146400
- [41] Li, R., Song, L., Quan, Q., Liu, M.-W., Chai, W., Lu, Q., . . . Chen, J.-Y. (2021). Detecting
 periprosthetic joint infection by using mass spectrometry. *J Bone Joint Surg*, *103*(20).
- [42] Trampuz, A., Piper, K. E., Jacobson, M. J., Hanssen, A. D., Unni, K. K., Osmon, D. R., ...
 Patel, R. (2007). Sonication of removed hip and knee prostheses for diagnosis of
 infection. *N Engl J Med*, *357*(7), 654-663. doi: 10.1056/NEJMoa061588
- [43] Piper, K. E., Jacobson, M. J., Cofield, R. H., Sperling, J. W., Sanchez-Sotelo, J., Osmon, D.
 R., . . . Patel, R. (2009). Microbiologic diagnosis of prosthetic shoulder infection by use of
 implant sonication. *J Clin Microbiol, 47*(6), 1878-1884. doi: 10.1128/JCM.01686-08

- [44] Kobayashi, H., Oethinger, M., Tuohy, M. J., Procop, G. W., & Bauer, T. W. (2009). Improved
 detection of biofilm-formative bacteria by vortexing and sonication: A pilot study. *Clin Orthop Relat Res, 467*(5), 1360-1364. doi: 10.1007/s11999-008-0609-5
- [45] Mangalaparthi, K. K., Chavan, S., Madugundu, A. K., Renuse, S., Vanderboom, P. M.,
 Maus, A. D., . . . Pandey, A. (2021). A SISCAPA-based approach for detection of SARSCoV-2 viral antigens from clinical samples. *Clin Proteomics, 18*(1), 25. doi:
 10.1186/s12014-021-09331-z
- [46] Renuse, S., Vanderboom, P. M., Maus, A. D., Kemp, J. V., Gurtner, K. M., Madugundu, A.
 K., . . . Pandey, A. (2021). A mass spectrometry-based targeted assay for detection of
 SARS-CoV-2 antigen from clinical specimens. *eBioMedicine*, *69*, 103465. doi:
 <u>https://doi.org/10.1016/j.ebiom.2021.103465</u>
- [47] Vanderboom, P. M., Mun, D.-G., Madugundu, A. K., Mangalaparthi, K. K., Saraswat, M., 454 Garapati, K., ... Pandey, A. (2021). Proteomic signature of host response to SARS-CoV-455 456 2 infection in the nasopharynx. Mole Cell Proteomics. 20. doi: 10.1016/j.mcpro.2021.100134 457
- [48] Chavan, S., Mangalaparthi, K. K., Singh, S., Renuse, S., Vanderboom, P. M., Madugundu,
 A. K., . . . Pandey, A. (2021). Mass spectrometric analysis of urine from COVID-19
 patients for detection of SARS-CoV-2 viral antigen and to study host response. J
 Proteome Res, 20(7), 3404-3413. doi: 10.1021/acs.jproteome.1c00391
- 462 [49] Parvizi, J., Tan, T. L., Goswami, K., Higuera, C., Della Valle, C., Chen, A. F., & Shohat, N. (2018). The 2018 definition of periprosthetic hip and knee infection: An evidence-based 463 and validated criteria. Arthroplasty. 1309-1314 e1302. 464 J 33(5). doi: 10.1016/j.arth.2018.02.078 465
- [50] Team", R. C. (2020). R: A language and environment for statistical computing: R Foundation
 for Statistical Computing, Vienna, Austria. Retrieved from https://www.R-project.org/
- [51] Gu Z, E. R., Schlesner M. (2016). Complex heatmaps reveal patterns and correlations in
 multidimensional genomic data. Retrieved from
 <u>https://www.bioconductor.org/packages/release/bioc/html/ComplexHeatmap.html</u>
- [52] Kassambara, A., & Mundt, F. (2020). factoextra: Extract and visualize the results of
 multivariate data analyses (Version R package version 1.0.7). Retrieved from
 https://CRAN.R-project.org/package=factoextra
- [53] Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., ... Ma'ayan, A.
 (2013). Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinform, 14*(1), 128. doi: 10.1186/1471-2105-14-128
- [54] Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., ...
 Ma'ayan, A. (2016). Enrichr: A comprehensive gene set enrichment analysis web server
 2016 update. *Nucleic Acids Res, 44*(W1), W90-W97. doi: 10.1093/nar/gkw377
- [55] Xie, Z., Bailey, A., Kuleshov, M. V., Clarke, D. J. B., Evangelista, J. E., Jenkins, S. L., ...
 Ma'ayan, A. (2021). Gene set knowledge discovery with Enrichr. *Curr Protoc*, 1(3), e90.
 doi: <u>https://doi.org/10.1002/cpz1.90</u>
- [56] Hood, M. I., & Skaar, E. P. (2012). Nutritional immunity: Transition metals at the pathogen–
 host interface. *Nat Rev Microbiol, 10*(8), 525-537. doi: 10.1038/nrmicro2836
- [57] Zackular, J. P., Chazin, W. J., & Skaar, E. P. (2015). Nutritional immunity: S100 proteins at
 the host-pathogen interface. *J Biol Chem*, 290(31), 18991-18998. doi:
 <u>https://doi.org/10.1074/jbc.R115.645085</u>
- [58] Núñez, G., Sakamoto, K., & Soares, M. P. (2018). Innate nutritional immunity. *J Immunol*, 201(1), 11. doi: 10.4049/jimmunol.1800325

- [59] Salari, P., Grassi, M., Cinti, B., Onori, N., & Gigante, A. (2020). Synovial fluid calprotectin
 for the preoperative diagnosis of chronic periprosthetic joint infection. *J Arthroplasty*,
 35(2), 534-537. doi: 10.1016/j.arth.2019.08.052
- [60] Peng, X., Zhang, H., Xin, P., Bai, G., Ge, Y., Cai, M., . . . Pang, Z. (2022). Synovial
 calprotectin for the diagnosis of periprosthetic joint infection: a diagnostic meta-analysis.
 J Orthop Surg Res, 17(1), 2. doi: 10.1186/s13018-021-02746-2
- [61] Assarsson, E., Lundberg, M., Holmquist, G., Björkesten, J., Thorsen, S. B., Ekman, D., ...
 Fredriksson, S. (2014). Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. *PLoS One, 9*(4), e95192-e95192. doi: 10.1371/journal.pone.0095192
- 500
 [62] Jemal, M. (2000). High-throughput quantitative bioanalysis by LC/MS/MS. Biomed

 501
 Chromatogr, 14(6), 422-429. doi: https://doi.org/10.1002/1099-0801(200010)14:6

 502
 0801(200010)14:6

503	Table 1. Proteins differentially abundant in Staphylococcus aureus periprosthetic joint
504	infection (PJI) versus non-infectious arthroplasty failure (NIAF) sonicate fluid samples by
505	liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Proteins with
506	increased and decreased abundance in S. aureus PJI compared to NIAF samples are unshaded
507	and shaded, respectively. Statistical significance was determined using 2-sample t-test p-values
508	≤0.05 and log ₂ fold-change values ≥2 or ≤-2. Data depicted are for NIAF (n=4) and <i>S. aureus</i> PJI
509	(n=4) sonicate fluid samples.

Protein description	Gene symbol	p-value	log ₂ Fold- change
Lactotransferrin	LTF	0.0061	5.198
Lipocalin-2	LCN2	0.0032	5.001
Myeloperoxidase	MPO	0.0084	4.896
Calprotectin (A9 subunit)	S100A9	0.0003	4.531
Cathepsin G	CTSG	0.0177	4.037
Calprotectin (A8 subunit)	S100A8	0.0119	3.951
Neutrophil elastase	ELANE	0.0128	3.780
Eosinophil cationic protein	RNASE3	0.0154	3.629
Endoplasmic reticulum to nucleus signaling 1	ERN1	0.0062	3.169
Matrix metalloproteinase-9	MMP9	0.0151	2.933
Lysozyme C	LYZ	0.0049	2.699
Haptoglobin	HP	0.0169	2.598
Lamin-B1	LMNB1	0.0007	2.492
Glycogen phosphorylase, liver form	PYGL	0.0059	2.471
Leucine-rich alpha-2-glycoprotein	LRG1	0.0067	2.169
Cathepsin D	CTSD	0.0385	-2.007
Fatty acid-binding protein, heart	FABP3	0.0197	-2.031
Fructose-1,6-bisphosphatase 1	FBP1	0.0218	-2.039
Fatty acid-binding protein, epidermal	FABP5	0.0222	-2.063
Collagen alpha-2(I) chain	COL1A2	0.0035	-2.085
Early endosome antigen 1	EEA1	0.0360	-2.111
Heat shock protein beta-1	HSPB1	0.0118	-2.127
Dihydrolipoamide S-succinyltransferase	DLST	0.0256	-2.304
Branched-chain-amino-acid aminotransferase	BCAT1	0.0151	-2.315
Annexin A2	ANXA2	0.0015	-2.363
Serpin B6	SERPINB6	0.0439	-2.384
CD44 antigen	CD44	0.0020	-2.451
Dermcidin	DCD	0.0435	-2.458
Ribonuclease pancreatic	RNASE1	0.0184	-2.541

Proteoglycan 4	PRG4	0.0037	-2.563
Beta-hexosaminidase subunit beta	HEXB	0.0494	-2.662
Osteopontin	SPP1	0.0099	-2.690
IFI30 lysosomal thiol reductase	IFI30	0.0237	-2.798
Cell surface glycoprotein MUC18	MCAM	0.0221	-4.240
Cartilage acidic protein 1	CRTAC1	0.0025	-5.297



Figure 1. Differential analysis of proteins identified in sonicate fluids from periprosthetic 510 joint infection (PJI) and non-infectious arthroplasty failure (NIAF) using liquid 511 chromatography-tandem mass spectrometry analysis. Volcano plot showing statistically 512 significant proteins differentially abundant in sonicate fluid from PJI cases. Proteins with 513 increased and decreased abundance were indicated in red and blue, respectively. The top five 514 DAPs are labelled. Vertical dashed lines designate log₂Fold-change value of ±2-fold and the 515 horizontal dashed line designates a p-value = 0.05. Statistical significance was determined 516 using 2-sample t-test with multiple hypothesis correction (p-values ≤0.05 and log₂fold-change 517 values ≥ 2 or ≤ -2). Data depicted are of NIAF (n=4) and S. aureus PJI (n=4) sonicate fluid 518 samples. 519



Figure 2. Differential abundant proteins clearly segregate sonicate fluid samples with *Staphylococcus aureus* periprosthetic joint infection (PJI) from non-infectious arthroplasty failure (NIAF). (A) Heatmap visualization of protein expression z-scores in NIAF and *S. aureus* PJI samples, with differentially abundant proteins and patient samples clustered. (B) Principal component analysis of NIAF and *S. aureus* PJI samples, with ellipses corresponding with 85% confidence intervals. Statistical significance was determined using 2sample t-test with multiple hypothesis correction (p-values ≤ 0.05 and \log_2 fold-change values ≥ 2 or ≤ -2). Data depicted are of NIAF (n=4) and *S. aureus* PJI (n=4) sonicate fluid samples.



Statistical significance

- 520 Figure 3. Gene ontology analysis of proteins differentially abundant in S. aureus
- 521 periprosthetic joint infection (PJI) versus non-infectious arthroplasty failure (NIAF)
- 522 sonicate fluid samples. (A) Biological processes and (B) Molecular functions enriched using
- the Gene Ontology 2021 knowledgebase. Gene ontology terms listed with those most
- statistically significant on top. Data depicted are of NIAF (n=4) and S. aureus PJI (n=4)
- 525 sonicate fluid samples.